Patent Expiry

Patent/Exclusivity Expiry: DUEXIS

Drug
DUEXIS

Other upcoming events for VKTX

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: DUEXIS — VKTX Patent Expiry | BioSniper